Pegaspargase Side Effects
Medically reviewed by Drugs.com. Last updated on Dec 11, 2022.
Applies to pegaspargase: parenteral injection.
Side effects include:
Grade 3 or 4 reactions: Hypoalbuminemia, elevated serum aminotransferase concentrations, febrile neutropenia, hypertriglyceridemia, hyperglycemia, hyperbilirubinemia, pancreatitis, clotting study abnormalities, embolic and thrombotic events, hypersensitivity reactions.
No apparent difference in adverse effects following IV versus IM administration.
For Healthcare Professionals
Applies to pegaspargase: injectable solution.
The most commonly reported side effects were elevated transaminases and clinical allergic reactions to asparaginase (including bronchospasm, hypotension, laryngeal edema, local erythema or swelling, systemic rash, and urticaria).[Ref]
Very common (10% or more): Hypersensitivity, urticaria, anaphylactic reaction[Ref]
Common (1% to 10%): Central nervous system thrombosis/hemorrhage, seizure, peripheral motor neuropathy, syncope
Rare (less than 0.1%): Posterior reversible leukoencephalopathy syndrome
Frequency not reported: Somnolence, tremor[Ref]
Common (1% to 10%): Thrombosis, embolism[Ref]
Very common (10% or more): Pancreatitis, diarrhea, abdominal pain, nausea
Common (1% to 10%): Vomiting, stomatitis, ascites
Rare (less than 0.1%): Pancreatitis necrotizing, pancreatitis hemorrhagic
Frequency not reported: Pancreatic pseudocyst, parotitis[Ref]
Very common (10% or more): Febrile neutropenia
Common (1% to 10%): Coagulopathy (prolonged prothrombin time or partial thromboplastin time; or hypofibrinogenemia), anemia
Frequency not reported: Bone marrow failure[Ref]
Very common (10% or more): Elevated transaminases
Common (1% to 10%): Hyperbilirubinemia, hepatotoxicity, fatty liver
Rare (0.01% to 0.1%): Hepatic necrosis, jaundice, cholestasis, hepatic failure[Ref]
Common (1% to 10%): Hyperglycemia, weight decreased, decreased appetite
Frequency not reported: Glucose intolerance, hyperlipidemia, hypercholesterolemia, diabetic ketoacidosis, hypoglycemia[Ref]
Common (1% to 10%): Infections, sepsis[Ref]
Common (1% to 10%): Pain in extremities[Ref]
Frequency not reported: Confusion[Ref]
Common (1% to 10%): Hypoxia[Ref]
Frequency not reported: Pyrexia[Ref]
Frequency not reported: Acute renal failure[Ref]
Very common (10% or more): Rash
Frequency not reported: Toxic epidermal necrolysis (TEN), cerebrovascular accident, hemorrhage, superior sagittal sinus thrombosis[Ref]
Frequently asked questions
More about pegaspargase
- Check interactions
- Compare alternatives
- Reviews (2)
- Dosage information
- During pregnancy
- Drug class: miscellaneous antineoplastics
- En español
Related treatment guides
1. "Product Information. Oncaspar (pegaspargase)." Rhone Poulenc Rorer (2001):
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Some side effects may not be reported. You may report them to the FDA.